This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

MCS in the Treatment of Lower Urinary Tract Symptoms (MCS_LUTS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Health Ever Bio-Tech Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01002417
First received: October 25, 2009
Last updated: March 1, 2015
Last verified: March 2015
  Purpose
The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Condition Intervention Phase
Lower Urinary Tract Symptoms Benign Prostatic Hyperplasia Drug: MCS-2 15 mg/day Drug: MCS-2 30 mg/day Drug: Placebo Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: An Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Study to Establish the Dosage, Efficacy, and Safety of MCS-2 in Treating Lower Urinary Tract Symptoms Suggestive of BPH in Treatment-Naive Male Subjects

Resource links provided by NLM:


Further study details as provided by Health Ever Bio-Tech Co., Ltd.:

Primary Outcome Measures:
  • Changes from baseline in International Prostate Symptom Scores [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Changes in I-PSS subscores [ Time Frame: 12 weeks ]
  • Changes in I-PSS QOL index [ Time Frame: 12 weeks ]
  • Changes in urine flow rate [ Time Frame: 12 weels ]
  • Incidence of treatment-emergent adverse events (TEAE) [ Time Frame: 12 weeks ]
  • Incidence of withdrawals due to TEAEs [ Time Frame: 12 weeks ]

Enrollment: 274
Study Start Date: July 2010
Study Completion Date: February 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Both the phase 2b and phase 3 parts of the study have the placebo arm.
Drug: Placebo
Two matching placebo soft-gel capsules, oral daily for 12 weeks.
Other Name: MCS matching placebo
Active Comparator: MCS-2 15 mg/day
For the phase 2b part of the study. It can also be used in the phase 3 part of the study if MCS-2 15 mg/day is selected as the optimal dosage.
Drug: MCS-2 15 mg/day
One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
Other Name: MUS
Drug: MCS-2 30 mg/day
Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
Other Name: MUS
Active Comparator: MCS-2 30 mg/day
For the phase 2b part of the study. It can also be used in the phase 3 part of the study if MCS-2 30 mg/day is selected as the optimal dosage.
Drug: MCS-2 15 mg/day
One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
Other Name: MUS
Drug: MCS-2 30 mg/day
Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
Other Name: MUS

Detailed Description:

This is an adaptive trial design, that combines elements of a Phase 2b (dose ranging) study and a Phase 3 (hypothesis testing) study, the objectives for the two phases are separate.

Phase 2b Objectives: The primary objective of the Phase 2b portion of this study is to evaluate, in a treatment-naïve population, the 0 mg (placebo), 15 mg, and 30 mg MCS-2 in terms of dose response and to determine the optimal dose to be used in the Phase 3 portion of this trial. The secondary objective of this portion of the study is to evaluate the safety and tolerability of the 15 mg and 30 mg MCS-2.

Phase 3 Objectives: The primary objective of the Phase 3 portion of this study is to evaluate, in a treatment-naïve population, the effectiveness of the MCS-2 (at the dosage determined in the Phase 2b portion of this study), as compared to MCS placebo (0 mg), in reducing the lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). The secondary objective of this study is to evaluate the safety and tolerability of MCS-2 (at the dosage determined in the Phase 2b portion of this study), as compared to MCS placebo (0 mg).

  Eligibility

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≧ 40 years old
  • Not being treated for BPH or LUTS
  • PSA ≦ 4 ng/ml and no pathologically-proven prostate cancer
  • I-PSS ≥ 10
  • No known malignancy
  • AST/ALT ≦ 3X UNL
  • Creatinine ≦ 3X UNL
  • Subjects who sign the informed consent form

Exclusion Criteria:

  • Subjects' LUTS are not BPH-related
  • Have been treated with pelvis irradiation or pelvic surgery
  • Plan to undergo any invasive procedures within the study period
  • Active infection or inflammation
  • Considered ineligible by the investigators
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01002417

Locations
United States, California
David Geffen School of Medicine at UCLA
Los Angeles, California, United States, 90095
Sponsors and Collaborators
Health Ever Bio-Tech Co., Ltd.
Investigators
Principal Investigator: Allan J Pantuck, MD, MS, FACS University of California, Los Angeles
  More Information

Responsible Party: Health Ever Bio-Tech Co., Ltd.
ClinicalTrials.gov Identifier: NCT01002417     History of Changes
Other Study ID Numbers: MCS-2-US-a
Study First Received: October 25, 2009
Last Updated: March 1, 2015

Keywords provided by Health Ever Bio-Tech Co., Ltd.:
Benign Prostatic Hyperplasia
Multi-carotenoids
MCS-2
Lower Urinary Tract Symptoms
International prostate symptom scores

Additional relevant MeSH terms:
Hyperplasia
Prostatic Hyperplasia
Lower Urinary Tract Symptoms
Pathologic Processes
Prostatic Diseases
Genital Diseases, Male
Urological Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on June 22, 2017